276 related articles for article (PubMed ID: 28748310)
21. Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC.
Cuvelier GDE; Logan BR; Prockop SE; Buckley RH; Kuo CY; Griffith LM; Liu X; Yip A; Hershfield MS; Ayoub PG; Moore TB; Dorsey MJ; O'Reilly RJ; Kapoor N; Pai SY; Kapadia M; Ebens CL; Forbes Satter LR; Burroughs LM; Petrovic A; Chellapandian D; Heimall J; Shyr DC; Rayes A; Bednarski JJ; Chandra S; Chandrakasan S; Gillio AP; Madden L; Quigg TC; Caywood EH; Dávila Saldaña BJ; DeSantes K; Eissa H; Goldman FD; Rozmus J; Shah AJ; Vander Lugt MT; Thakar MS; Parrott RE; Martinez C; Leiding JW; Torgerson TR; Pulsipher MA; Notarangelo LD; Cowan MJ; Dvorak CC; Haddad E; Puck JM; Kohn DB
Blood; 2022 Aug; 140(7):685-705. PubMed ID: 35671392
[TBL] [Abstract][Full Text] [Related]
22. Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency.
Ferrua F; Brigida I; Aiuti A
Curr Opin Allergy Clin Immunol; 2010 Dec; 10(6):551-6. PubMed ID: 20966749
[TBL] [Abstract][Full Text] [Related]
23. Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency.
Migliavacca M; Barzaghi F; Fossati C; Rancoita PMV; Gabaldo M; Dionisio F; Giannelli S; Salerio FA; Ferrua F; Tucci F; Calbi V; Gallo V; Recupero S; Consiglieri G; Pajno R; Sambuco M; Priolo A; Ferri C; Garella V; Monti I; Silvani P; Darin S; Casiraghi M; Corti A; Zancan S; Levi M; Cesana D; Carlucci F; Pituch-Noworolska A; AbdElaziz D; Baumann U; Finocchi A; Cancrini C; Ladogana S; Meinhardt A; Meyts I; Montin D; Notarangelo LD; Porta F; Pasquet M; Speckmann C; Stepensky P; Tommasini A; Rabusin M; Karakas Z; Galicchio M; Leonardi L; Duse M; Guner SN; Di Serio C; Ciceri F; Bernardo ME; Aiuti A; Cicalese MP
Nat Med; 2024 Feb; 30(2):488-497. PubMed ID: 38355973
[TBL] [Abstract][Full Text] [Related]
24. Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients.
Hashem H; Bucciol G; Ozen S; Unal S; Bozkaya IO; Akarsu N; Taskinen M; Koskenvuo M; Saarela J; Dimitrova D; Hickstein DD; Hsu AP; Holland SM; Krance R; Sasa G; Kumar AR; Müller I; de Sousa MA; Delafontaine S; Moens L; Babor F; Barzaghi F; Cicalese MP; Bredius R; van Montfrans J; Baretta V; Cesaro S; Stepensky P; Benedicte N; Moshous D; Le Guenno G; Boutboul D; Dalal J; Brooks JP; Dokmeci E; Dara J; Lucas CL; Hambleton S; Wilson K; Jolles S; Koc Y; Güngör T; Schnider C; Candotti F; Steinmann S; Schulz A; Chambers C; Hershfield M; Ombrello A; Kanakry JA; Meyts I
J Clin Immunol; 2021 Oct; 41(7):1633-1647. PubMed ID: 34324127
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis, Treatment and Long-Term Follow Up of Patients with ADA Deficiency: a Single-Center Experience.
Baffelli R; Notarangelo LD; Imberti L; Hershfield MS; Serana F; Santisteban I; Bolda F; Porta F; Lanfranchi A
J Clin Immunol; 2015 Oct; 35(7):624-37. PubMed ID: 26376800
[TBL] [Abstract][Full Text] [Related]
26. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.
Candotti F; Shaw KL; Muul L; Carbonaro D; Sokolic R; Choi C; Schurman SH; Garabedian E; Kesserwan C; Jagadeesh GJ; Fu PY; Gschweng E; Cooper A; Tisdale JF; Weinberg KI; Crooks GM; Kapoor N; Shah A; Abdel-Azim H; Yu XJ; Smogorzewska M; Wayne AS; Rosenblatt HM; Davis CM; Hanson C; Rishi RG; Wang X; Gjertson D; Yang OO; Balamurugan A; Bauer G; Ireland JA; Engel BC; Podsakoff GM; Hershfield MS; Blaese RM; Parkman R; Kohn DB
Blood; 2012 Nov; 120(18):3635-46. PubMed ID: 22968453
[TBL] [Abstract][Full Text] [Related]
27. Adenosine deaminase deficiency: a review.
Flinn AM; Gennery AR
Orphanet J Rare Dis; 2018 Apr; 13(1):65. PubMed ID: 29690908
[TBL] [Abstract][Full Text] [Related]
28. First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature.
Migliavacca M; Assanelli A; Ponzoni M; Pajno R; Barzaghi F; Giglio F; Ferrua F; Frittoli M; Brigida I; Dionisio F; Nicoletti R; Casiraghi M; Roncarolo MG; Doglioni C; Peccatori J; Ciceri F; Cicalese MP; Aiuti A
Front Immunol; 2018; 9():113. PubMed ID: 29456531
[TBL] [Abstract][Full Text] [Related]
29. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
[TBL] [Abstract][Full Text] [Related]
30. Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID): Molecular Pathogenesis and Clinical Manifestations.
Bradford KL; Moretti FA; Carbonaro-Sarracino DA; Gaspar HB; Kohn DB
J Clin Immunol; 2017 Oct; 37(7):626-637. PubMed ID: 28842866
[TBL] [Abstract][Full Text] [Related]
31. Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications.
Hönig M; Albert MH; Schulz A; Sparber-Sauer M; Schütz C; Belohradsky B; Güngör T; Rojewski MT; Bode H; Pannicke U; Lippold D; Schwarz K; Debatin KM; Hershfield MS; Friedrich W
Blood; 2007 Apr; 109(8):3595-602. PubMed ID: 17185467
[TBL] [Abstract][Full Text] [Related]
32. Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
Aiuti A; Cattaneo F; Galimberti S; Benninghoff U; Cassani B; Callegaro L; Scaramuzza S; Andolfi G; Mirolo M; Brigida I; Tabucchi A; Carlucci F; Eibl M; Aker M; Slavin S; Al-Mousa H; Al Ghonaium A; Ferster A; Duppenthaler A; Notarangelo L; Wintergerst U; Buckley RH; Bregni M; Marktel S; Valsecchi MG; Rossi P; Ciceri F; Miniero R; Bordignon C; Roncarolo MG
N Engl J Med; 2009 Jan; 360(5):447-58. PubMed ID: 19179314
[TBL] [Abstract][Full Text] [Related]
33. Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency.
Kohn DB; Booth C; Shaw KL; Xu-Bayford J; Garabedian E; Trevisan V; Carbonaro-Sarracino DA; Soni K; Terrazas D; Snell K; Ikeda A; Leon-Rico D; Moore TB; Buckland KF; Shah AJ; Gilmour KC; De Oliveira S; Rivat C; Crooks GM; Izotova N; Tse J; Adams S; Shupien S; Ricketts H; Davila A; Uzowuru C; Icreverzi A; Barman P; Campo Fernandez B; Hollis RP; Coronel M; Yu A; Chun KM; Casas CE; Zhang R; Arduini S; Lynn F; Kudari M; Spezzi A; Zahn M; Heimke R; Labik I; Parrott R; Buckley RH; Reeves L; Cornetta K; Sokolic R; Hershfield M; Schmidt M; Candotti F; Malech HL; Thrasher AJ; Gaspar HB
N Engl J Med; 2021 May; 384(21):2002-2013. PubMed ID: 33974366
[TBL] [Abstract][Full Text] [Related]
34. Bone marrow transplantation and alternatives for adenosine deaminase deficiency.
Gaspar HB
Immunol Allergy Clin North Am; 2010 May; 30(2):221-36. PubMed ID: 20493398
[TBL] [Abstract][Full Text] [Related]
35. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.
Carbonaro DA; Zhang L; Jin X; Montiel-Equihua C; Geiger S; Carmo M; Cooper A; Fairbanks L; Kaufman ML; Sebire NJ; Hollis RP; Blundell MP; Senadheera S; Fu PY; Sahaghian A; Chan RY; Wang X; Cornetta K; Thrasher AJ; Kohn DB; Gaspar HB
Mol Ther; 2014 Mar; 22(3):607-622. PubMed ID: 24256635
[TBL] [Abstract][Full Text] [Related]
36. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.
Ferrua F; Aiuti A
Hum Gene Ther; 2017 Nov; 28(11):972-981. PubMed ID: 28847159
[TBL] [Abstract][Full Text] [Related]
37. Gene therapy for ADA-SCID, the first marketing approval of an
Aiuti A; Roncarolo MG; Naldini L
EMBO Mol Med; 2017 Jun; 9(6):737-740. PubMed ID: 28396566
[TBL] [Abstract][Full Text] [Related]
38. Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006).
Booth C; Hershfield M; Notarangelo L; Buckley R; Hoenig M; Mahlaoui N; Cavazzana-Calvo M; Aiuti A; Gaspar HB
Clin Immunol; 2007 May; 123(2):139-47. PubMed ID: 17300989
[TBL] [Abstract][Full Text] [Related]
39. Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency.
Montiel-Equihua CA; Thrasher AJ; Gaspar HB
Curr Gene Ther; 2012 Feb; 12(1):57-65. PubMed ID: 22348551
[TBL] [Abstract][Full Text] [Related]
40. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID.
Bordignon C; Mavilio F; Ferrari G; Servida P; Ugazio AG; Notarangelo LD; Gilboa E; Rossini S; O'Reilly RJ; Smith CA
Hum Gene Ther; 1993 Aug; 4(4):513-20. PubMed ID: 8399494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
